

Ming Yi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/116603/ming-yi-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49
papers

2,463
citations

23
h-index

49
g-index

52
ext. papers

3,951
ext. citations

13
avg, IF

5.92
L-index

| # | Paper | IF | Citations |
|----|--|------|-----------|
| 49 | Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. <i>Molecular Cancer</i> , 2019 , 18, 155 | 42.1 | 353 |
| 48 | MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. <i>Journal of Clinical Investigation</i> , 2014 , 124, 398-412 | 15.9 | 281 |
| 47 | Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. <i>Molecular Cancer</i> , 2018 , 17, 129 | 42.1 | 280 |
| 46 | Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. <i>Molecular Cancer</i> , 2019 , 18, 60 | 42.1 | 169 |
| 45 | Organoid technology and applications in cancer research. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 116 | 22.4 | 123 |
| 44 | Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. <i>Molecular Cancer</i> , 2019 , 18, 125 | 42.1 | 113 |
| 43 | Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 27 | 22.4 | 107 |
| 42 | Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 35 | 22.4 | 98 |
| 41 | Gut microbiome modulates efficacy of immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018 , 11, 47 | 22.4 | 76 |
| 40 | The role of cancer-derived microRNAs in cancer immune escape. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 25 | 22.4 | 74 |
| 39 | Regulation of PD-L1 expression in the tumor microenvironment. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 10 | 22.4 | 65 |
| 38 | Prospects for combining immune checkpoint blockade with PARP inhibition. <i>Journal of Hematology and Oncology</i> , 2019 , 12, 98 | 22.4 | 63 |
| 37 | The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018 , 7, 28 | 7.8 | 63 |
| 36 | The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 72 | 22.4 | 55 |
| 35 | Advances and perspectives of PARP inhibitors. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 29 | 7.8 | 52 |
| 34 | Blocking TGF- β signaling to enhance the efficacy of immune checkpoint inhibitor. <i>OncoTargets and Therapy</i> , 2019 , 12, 9527-9538 | 4.4 | 48 |
| 33 | The efficacy and safety of combination of PD-1 and CTLA-4 inhibitors: a meta-analysis. <i>Experimental Hematology and Oncology</i> , 2019 , 8, 26 | 7.8 | 32 |

| | | | |
|----|---|------|----|
| 32 | The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF- β and PD-L1. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 27 | 22.4 | 30 |
| 31 | The application of histone deacetylases inhibitors in glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020 , 39, 138 | 12.8 | 29 |
| 30 | The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. <i>International Journal of Cancer</i> , 2021 , 148, 2640-2651 | 7.5 | 28 |
| 29 | Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 18 | 7.8 | 27 |
| 28 | Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2021 , 70, 1705-1719 | 7.4 | 26 |
| 27 | Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy. <i>Integrative Cancer Therapies</i> , 2019 , 18, 1534735419876351 | 3 | 23 |
| 26 | Combination strategies with PD-1/PD-L1 blockade: current advances and future directions.. <i>Molecular Cancer</i> , 2022 , 21, 28 | 42.1 | 22 |
| 25 | The roles of exosomes in cancer drug resistance and its therapeutic application. <i>Clinical and Translational Medicine</i> , 2020 , 10, e257 | 5.7 | 20 |
| 24 | MiRNA-mediated EMT and CSCs in cancer chemoresistance. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 12 | 7.8 | 18 |
| 23 | CXCL1 as an Unfavorable Prognosis Factor Negatively Regulated by DACH1 in Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2019 , 9, 1515 | 5.3 | 15 |
| 22 | Identifying Tumorigenesis and Prognosis-Related Genes of Lung Adenocarcinoma: Based on Weighted Gene Coexpression Network Analysis. <i>BioMed Research International</i> , 2020 , 2020, 4169691 | 3 | 13 |
| 21 | Epidemiological trends of women's cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study. <i>Biomarker Research</i> , 2021 , 9, 55 | 8 | 13 |
| 20 | Combine and conquer: manganese synergizing anti-TGF- β /PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. <i>Journal of Hematology and Oncology</i> , 2021 , 14, 146 | 22.4 | 13 |
| 19 | The regulation of cytokine signaling by retinal determination gene network pathway in cancer. <i>OncoTargets and Therapy</i> , 2018 , 11, 6479-6487 | 4.4 | 11 |
| 18 | Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017. <i>Aging</i> , 2020 , 12, 22869-22891 | 9.9 | 10 |
| 17 | Distinct Roles of VEGFA and ANGPT2 in Lung Adenocarcinoma and Squamous Cell Carcinoma. <i>Journal of Cancer</i> , 2020 , 11, 153-167 | 4.5 | 9 |
| 16 | The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 27 | 7.8 | 8 |
| 15 | Prognostic Values of TIM-3 Expression in Patients With Solid Tumors: A Meta-Analysis and Database Evaluation. <i>Frontiers in Oncology</i> , 2020 , 10, 1288 | 5.3 | 8 |

| | | | |
|----|---|------|---|
| 14 | CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 1295-1308 | 5.9 | 8 |
| 13 | Progression and prognostic value of ECT2 in non-small-cell lung cancer and its correlation with PCNA. <i>Cancer Management and Research</i> , 2018 , 10, 4039-4050 | 3.6 | 8 |
| 12 | Roles of Microvesicles in Tumor Progression and Clinical Applications. <i>International Journal of Nanomedicine</i> , 2021 , 16, 7071-7090 | 7.3 | 7 |
| 11 | EYA2 Correlates With Clinico-Pathological Features of Breast Cancer, Promotes Tumor Proliferation, and Predicts Poor Survival. <i>Frontiers in Oncology</i> , 2019 , 9, 26 | 5.3 | 6 |
| 10 | RDGN-based predictive model for the prognosis of breast cancer. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 13 | 7.8 | 5 |
| 9 | Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies.. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 60 | 7.8 | 5 |
| 8 | Advances of Targeted Therapy for Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021 , 11, 719896 | 5.3 | 5 |
| 7 | Recent advances and challenges of bispecific antibodies in solid tumors.. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 56 | 7.8 | 5 |
| 6 | Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.. <i>Theranostics</i> , 2022 , 12, 747-766 | 12.1 | 4 |
| 5 | Upregulation of STAT1-CCL5 axis is a biomarker of colon cancer and promotes the proliferation of colon cancer cells. <i>Annals of Translational Medicine</i> , 2020 , 8, 951 | 3.2 | 4 |
| 4 | Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer.. <i>Frontiers in Immunology</i> , 2022 , 13, 827921 | 8.4 | 4 |
| 3 | The biology of combination immunotherapy in recurrent metastatic head and neck cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2021 , 136, 106002 | 5.6 | 3 |
| 2 | Propofol target-controlled infusion modeling in rabbits: Pharmacokinetic and pharmacodynamic analysis. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016 , 36, 428-433 | | 3 |
| 1 | Prognostic significance of KRT19 in Lung Squamous Cancer. <i>Journal of Cancer</i> , 2021 , 12, 1240-1248 | 4.5 | 3 |